Serum fatty acid synthase as a marker of pancreatic neoplasia

Kim Walter, Seung Mo Hong, Sinead Nyhan, Marcia Canto, Neal S Fedarko, Alison Klein, Margaret Griffith, Noriyuki Omura, Susan Medghalchi, Frank Kuhajda, Michael S Goggins

Research output: Contribution to journalArticle

Abstract

Markers of early pancreatic cancer and its precursors are needed to improve the uniformly poor prognosis of this disease. Fatty acid synthase (FAS) catalyzes the synthesis of long-chain fatty acids and is overexpressed in most human solid tumors. We therefore evaluated serum FAS as a marker of pancreatic adenocarcinoma. FAS expression patterns in primary pancreatic adenocarcinomas, intraductal papillary mucinous neoplasms (IPMN), and chronic pancreatitis tissues were analyzed by immunohistochemistry. Serum FAS levels were determined by ELISA in 102 patients with pancreatic adenocarcinomas, in 42 patients with IPMNs, in 27 patients with chronic pancreatitis, and in 39 healthy control subjects. FAS protein was overexpressed in the ductal epithelium of 343 of 399 primary pancreatic adenocarcinomas (86.0%) and 28 of 30 IPMNs (93.3%), and in the islet and ductal cells in 3 of 54chronic pancreatitis tissues (5.6%), whereas normal ductal epithelium lacked FAS expression. Serum FAS levels were significantly higher in patients with pancreatic ductal adenocarcinoma (first quartile median, 22.0; 4.5 ng/mL), in patients with IPMNs (20.7; 9.4ng/m L), and in patients with chronic pancreatitis (31.1; 11.9 ng/mL) than in healthy controls (0; 0 ng/mL). FAS levels declined postoperatively in 8 of 9 patients with pancreatic adenocarcinoma and elevations of their preoperative serum FAS. In conclusion, serum FAS levels are elevated in patients with pancreatic cancer and IPMNs and are associated with neoplastic overexpression of FAS.

Original languageEnglish (US)
Pages (from-to)2380-2385
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume18
Issue number9
DOIs
StatePublished - Sep 2009

Fingerprint

Fatty Acid Synthases
Serum
Neoplasms
Adenocarcinoma
Chronic Pancreatitis
Pancreatic Neoplasms
Epithelium
Papillary Adenocarcinoma
Islets of Langerhans
Pancreatitis
Healthy Volunteers
Fatty Acids
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Serum fatty acid synthase as a marker of pancreatic neoplasia. / Walter, Kim; Hong, Seung Mo; Nyhan, Sinead; Canto, Marcia; Fedarko, Neal S; Klein, Alison; Griffith, Margaret; Omura, Noriyuki; Medghalchi, Susan; Kuhajda, Frank; Goggins, Michael S.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 18, No. 9, 09.2009, p. 2380-2385.

Research output: Contribution to journalArticle

Walter, Kim ; Hong, Seung Mo ; Nyhan, Sinead ; Canto, Marcia ; Fedarko, Neal S ; Klein, Alison ; Griffith, Margaret ; Omura, Noriyuki ; Medghalchi, Susan ; Kuhajda, Frank ; Goggins, Michael S. / Serum fatty acid synthase as a marker of pancreatic neoplasia. In: Cancer Epidemiology Biomarkers and Prevention. 2009 ; Vol. 18, No. 9. pp. 2380-2385.
@article{9c899d9f48ba420aa8efc26d3b809d82,
title = "Serum fatty acid synthase as a marker of pancreatic neoplasia",
abstract = "Markers of early pancreatic cancer and its precursors are needed to improve the uniformly poor prognosis of this disease. Fatty acid synthase (FAS) catalyzes the synthesis of long-chain fatty acids and is overexpressed in most human solid tumors. We therefore evaluated serum FAS as a marker of pancreatic adenocarcinoma. FAS expression patterns in primary pancreatic adenocarcinomas, intraductal papillary mucinous neoplasms (IPMN), and chronic pancreatitis tissues were analyzed by immunohistochemistry. Serum FAS levels were determined by ELISA in 102 patients with pancreatic adenocarcinomas, in 42 patients with IPMNs, in 27 patients with chronic pancreatitis, and in 39 healthy control subjects. FAS protein was overexpressed in the ductal epithelium of 343 of 399 primary pancreatic adenocarcinomas (86.0{\%}) and 28 of 30 IPMNs (93.3{\%}), and in the islet and ductal cells in 3 of 54chronic pancreatitis tissues (5.6{\%}), whereas normal ductal epithelium lacked FAS expression. Serum FAS levels were significantly higher in patients with pancreatic ductal adenocarcinoma (first quartile median, 22.0; 4.5 ng/mL), in patients with IPMNs (20.7; 9.4ng/m L), and in patients with chronic pancreatitis (31.1; 11.9 ng/mL) than in healthy controls (0; 0 ng/mL). FAS levels declined postoperatively in 8 of 9 patients with pancreatic adenocarcinoma and elevations of their preoperative serum FAS. In conclusion, serum FAS levels are elevated in patients with pancreatic cancer and IPMNs and are associated with neoplastic overexpression of FAS.",
author = "Kim Walter and Hong, {Seung Mo} and Sinead Nyhan and Marcia Canto and Fedarko, {Neal S} and Alison Klein and Margaret Griffith and Noriyuki Omura and Susan Medghalchi and Frank Kuhajda and Goggins, {Michael S}",
year = "2009",
month = "9",
doi = "10.1158/1055-9965.EPI-09-0144",
language = "English (US)",
volume = "18",
pages = "2380--2385",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Serum fatty acid synthase as a marker of pancreatic neoplasia

AU - Walter, Kim

AU - Hong, Seung Mo

AU - Nyhan, Sinead

AU - Canto, Marcia

AU - Fedarko, Neal S

AU - Klein, Alison

AU - Griffith, Margaret

AU - Omura, Noriyuki

AU - Medghalchi, Susan

AU - Kuhajda, Frank

AU - Goggins, Michael S

PY - 2009/9

Y1 - 2009/9

N2 - Markers of early pancreatic cancer and its precursors are needed to improve the uniformly poor prognosis of this disease. Fatty acid synthase (FAS) catalyzes the synthesis of long-chain fatty acids and is overexpressed in most human solid tumors. We therefore evaluated serum FAS as a marker of pancreatic adenocarcinoma. FAS expression patterns in primary pancreatic adenocarcinomas, intraductal papillary mucinous neoplasms (IPMN), and chronic pancreatitis tissues were analyzed by immunohistochemistry. Serum FAS levels were determined by ELISA in 102 patients with pancreatic adenocarcinomas, in 42 patients with IPMNs, in 27 patients with chronic pancreatitis, and in 39 healthy control subjects. FAS protein was overexpressed in the ductal epithelium of 343 of 399 primary pancreatic adenocarcinomas (86.0%) and 28 of 30 IPMNs (93.3%), and in the islet and ductal cells in 3 of 54chronic pancreatitis tissues (5.6%), whereas normal ductal epithelium lacked FAS expression. Serum FAS levels were significantly higher in patients with pancreatic ductal adenocarcinoma (first quartile median, 22.0; 4.5 ng/mL), in patients with IPMNs (20.7; 9.4ng/m L), and in patients with chronic pancreatitis (31.1; 11.9 ng/mL) than in healthy controls (0; 0 ng/mL). FAS levels declined postoperatively in 8 of 9 patients with pancreatic adenocarcinoma and elevations of their preoperative serum FAS. In conclusion, serum FAS levels are elevated in patients with pancreatic cancer and IPMNs and are associated with neoplastic overexpression of FAS.

AB - Markers of early pancreatic cancer and its precursors are needed to improve the uniformly poor prognosis of this disease. Fatty acid synthase (FAS) catalyzes the synthesis of long-chain fatty acids and is overexpressed in most human solid tumors. We therefore evaluated serum FAS as a marker of pancreatic adenocarcinoma. FAS expression patterns in primary pancreatic adenocarcinomas, intraductal papillary mucinous neoplasms (IPMN), and chronic pancreatitis tissues were analyzed by immunohistochemistry. Serum FAS levels were determined by ELISA in 102 patients with pancreatic adenocarcinomas, in 42 patients with IPMNs, in 27 patients with chronic pancreatitis, and in 39 healthy control subjects. FAS protein was overexpressed in the ductal epithelium of 343 of 399 primary pancreatic adenocarcinomas (86.0%) and 28 of 30 IPMNs (93.3%), and in the islet and ductal cells in 3 of 54chronic pancreatitis tissues (5.6%), whereas normal ductal epithelium lacked FAS expression. Serum FAS levels were significantly higher in patients with pancreatic ductal adenocarcinoma (first quartile median, 22.0; 4.5 ng/mL), in patients with IPMNs (20.7; 9.4ng/m L), and in patients with chronic pancreatitis (31.1; 11.9 ng/mL) than in healthy controls (0; 0 ng/mL). FAS levels declined postoperatively in 8 of 9 patients with pancreatic adenocarcinoma and elevations of their preoperative serum FAS. In conclusion, serum FAS levels are elevated in patients with pancreatic cancer and IPMNs and are associated with neoplastic overexpression of FAS.

UR - http://www.scopus.com/inward/record.url?scp=70349318549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349318549&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-09-0144

DO - 10.1158/1055-9965.EPI-09-0144

M3 - Article

C2 - 19723916

AN - SCOPUS:70349318549

VL - 18

SP - 2380

EP - 2385

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 9

ER -